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GDF-8Loss of muscle and bone mass with age are signiﬁcant contributors to falls and fractures among the elderly.
Myostatin deﬁciency is associated with increased muscle mass in mice, dogs, cows, sheep and humans, and mice
lacking myostatin have been observed to show increased bone density in the limb, spine, and jaw. Transgenic
overexpression of myostatin propeptide, which binds to and inhibits the active myostatin ligand, also increases
muscle mass and bone density in mice. We therefore sought to test the hypothesis that in vivo inhibition of
myostatin using an injectable myostatin propeptide (GDF8 propeptide-Fc) would increase both muscle mass and
bone density in aged (24 mo) mice. Male mice were injected weekly (20 mg/kg body weight) with recombinant
myostatin propeptide-Fc (PRO) or vehicle (VEH; saline) for fourweeks. Therewas nodifference in bodyweight be-
tween the two groups at the end of the treatment period, but PRO treatment signiﬁcantly increased mass of the
tibialis anterior muscle (+7%) and increased muscle ﬁber diameter of the extensor digitorum longus (+16%)
and soleus (+6%) muscles compared to VEH treatment. Bone volume relative to total volume (BV/TV) of the
femur calculated by microCT did not differ signiﬁcantly between PRO- and VEH-treated mice, and ultimate
force (Fu), stiffness (S), toughness (U) measured from three-point bending tests also did not differ signiﬁcantly
between groups. Histomorphometric assays also revealed no differences in bone formation or resorption in
response to PRO treatment. These data suggest that while developmental perturbation of myostatin signaling
through either gene knockout or transgenic inhibition may alter bothmuscle and bonemass inmice, pharmaco-
logical inhibition of myostatin in aged mice has a more pronounced effect on skeletal muscle than on bone.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Globally, the size of the aging population is increasing rapidly, and
as a corollary the prevalence of age-related musculoskeletal disorders
such as osteoarthritis, sarcopenia, and osteoporosis is also increasing
(Sànchez-Riera et al., 2010). A primary contributor to themorbidity and
mortality associated with aging is an increased frequency of falls, and
falls are often accompanied by bone fractures. Indeed, falls are the pri-
mary factor in more than 90% of bone fractures (Jarvinen et al., 2008).
In many cases bone fractures limit subsequent capacity for normallogy & Anatomy, LaneyWalker
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c. Open access under CC BY-NC-ND licensedaily activities, ambulation, and independence, ultimately leading to
assisted living situations which can be ﬁnancially burdensome. The
disability following a fall and fracture also contributes directly to an
increase in comorbidities such as respiratory infections, which in turn
contribute to greater overall age-related mortality (Bertram et al.,
2011).
The growth, development, and aging of muscle and bone are closely
linked. Pediatric gains in bone mass are normally preceded by gains in
muscle mass, and loss of muscle mass with age typically precedes
peak rates of loss in bone density (Hamrick et al., 2010a). The close cou-
pling of muscle and bone across the lifespan therefore suggests that
changes in one tissue may be mechanistically linked with changes in
another. Indeed, there are multiple mechanisms linking the two tissues
such asmechanical loading,muscle-derived trophic factors (myokines),
as well as systemic factors such as sex steroids and growth factors that
have anabolic effects on both muscle and bone. The functional and per-
haps molecular integration between the two tissues therefore suggests
that therapeutic strategies targeting one particular tissue may have. 
Fig. 1.Myostatin-induced luciferase activity declines signiﬁcantly with increasing con-
centration of myostatin propeptide. The pGL3(CAGA)12— neo reporter vector contains
12 CAGA boxes previously reported to be TGFβ-responsive elements (Dennler et al.
(1998) EMBO J. 17:3091–3100), a neo resistance gene, and the basic luciferase reporter
plasmid pGL3 (Promega Corporation).
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(e.g., androgen-receptor modulators, vitamin D receptor agonists)
could positively impact both tissues at once (Hamrick, 2010, 2011,
2012).
Given the very close linkages between muscle and bone referenced
above, we sought to test the hypothesis that pharmacologic inhibition
of myostatin (GDF-8) could increase both muscle and bone mass in an
aged animal model. Our rationale for pursuing this hypothesis is
based on several key observations. The ﬁrst is that mice lacking
myostatin show increased muscle mass as well as increased bone den-
sity in the spine, limb, and jaw (Elkasrawy andHamrick, 2010). The sec-
ond is that recent studies have demonstrated that a myostatin antibody
(LeBrasseur et al., 2009;Murphy et al., 2010) and a decoy myostatin re-
ceptor (Chiu et al., 2013) can increase muscle mass in aged mice. The
decoy receptor (ActR-IIB) was also found to increase bone formation
and bone density (Chiu et al., 2013). It should, however, be pointed
out that the antibody and decoy receptor function through slightly dif-
ferent mechanisms, as the antibody is myostatin speciﬁc but the decoy
receptor can bind ligands other thanmyostatin such as activins and var-
ious bone morphogenetic proteins (Souza et al., 2008). These ﬁndings
suggest that therapeutic modulation of myostatin in vivo may be an
effective strategy for preserving muscle and bone mass with age, and
sowe employed amousemodel to evaluate this hypothesis. Speciﬁcally,
we have previously shown that C57BL6 mice lose signiﬁcant muscle
mass, bone density, and bone strength with age, such that mice
24 months of age show amarked decrease in thesemeasures compared
to mice at 12 months of age (Hamrick et al., 2006a). This study utilizes
myostatin propeptide treatment in aged (24 months) C57BL6 mice as
an in vivo model for assessing the potential effects of myostatin inhibi-
tion on age associatedmuscle and bone loss. The propeptide fragment is
utilized here because it has previously been shown to enhance muscle
and bone repair in vivo, and binds the active myostatin ligand with
high afﬁnity (Bogdanovich et al., 2005; Hamrick et al, 2010b).
2. Materials and methods
2.1. Production and validation of myostatin propeptide
The myostatin propeptide-Fc fusion protein was produced in CHO
cells as described previously (Jiang et al., 2004). Tomeasure the activity
of myostatin and the efﬁcacy of the myostatin propeptide a luciferase
reporter gene assay was developed where the vector pGL3(CAGA)
12-neo was stably transfected into A204 (human rhabdomyosarcoma)
cells. Addition of myostatin to the A204 CAGA cells, and the binding of
myostatin to its receptors, initiates the Smad signal transduction path-
way and activates the luciferase reporter gene. The level of activation
is proportional to the luciferase activity and the linear portion of the
activity curve is in the ng/ml range (Fig. 1), which is what is expected
for a protein in the TGFβ superfamily. The addition of the myostatin
propeptide prevents the binding of myostatin to its receptors, and the
IC50 for the propeptide is approximately 2.0 nM (Fig. 1). There is high
sequence homology between GDF-8 and GDF-11, and the propeptide
is also capable of binding GDF-11 (McPherron, 2010).
2.2. Animals and treatment for aging study
Male C57BL6 mice were purchased from the aged rodent colony at
the National Institute on Aging, National Institutes of Health (USA) at
22 months of age and delivered to Georgia Regents University,
Augusta GA. Animals were allowed to acclimate for one week and
were maintained at the Laboratory Animal Service Facility of Georgia
Regents University. An earlier dose–response study was used to eval-
uate the efﬁcacy of a myostatin propeptide in vivo (Hamrick et al.,
2010b). Adult mice (5–6 months) were treated with the propeptide
at 0, 10, 20, or 50 mg/kg at days 0, 5, and 10 and then sacriﬁced one
week after the last treatment. Those data showed that propeptidetreatment increased fore- and hindlimb muscle mass by 10% at the
10 mg/kg dose and increased muscle mass by more than 15% at the
20 mg/kg dose, but the 50 mg/kg dose did not increasemusclemass be-
yond the increase observed in the 20 mg/kg group (Hamrick et al.,
2010b). The 20 mg/kg dose was therefore used in this study. Mice were
divided into two treatment groups: a vehicle group (VEH; n = 14) and
a myostatin propeptide group (PRO; n = 15). Mice received i.p. injec-
tions every ﬁve days for 25 days with a dosage of 20 mg/kg body weight
at a volume of 0.2 ml. Myostatin propeptide [4.48 mg/ml] was obtained
from Pﬁzer Inc. (Cambridge, MA, USA). Micewere given calcein i.p. injec-
tions to label actively mineralizing bone surfaces four days and 24 hours
prior to sacriﬁce.
2.3. Tissue collection
Animals were euthanized by CO2 overdose and thoracotomy follow-
ing procedures approved by the Institutional Animal Care andUse Com-
mittee of Georgia Regents University. The extensor digitorum longus
(EDL) and soleus (SOL) muscles from one limb were dissected out, cut
in half and embedded in OCT for cryostat sectioning and muscle ﬁber
size measurements. The tibialis anterior from one limb was dissected
out, weighed, snap frozen and homogenized for RT-PCR of the following
myogenicmarkers:myostatin,Mafbx,Murf 1,MHC, and IGF-1. The right
tibias were disarticulated and ﬁxed in 70% ethanol for μCT and plastic
sectioning while the left tibias were stored damp at minus 20 °C for
biomechanical testing followed by RT-PCR for bone formation and oste-
oblast differentiationmarkers Runx2, Osx and BMP-2. The femora were
ﬁxed in 4% paraformaldehyde, decalciﬁed and embedded in parafﬁn for
sectioning and stained for osteoclasts (TRAP kit from Sigma 386A-1KT)
and osteoblasts (Celestine blue/Van Gieson's).
2.4. Bone histomorphometry
Osteoblast and osteoclast counts were performed as previously de-
scribed (Wenger et al., 2010) on 4–5 μm sections after the specimens
were decalciﬁed in 4% EDTA for 1 week, dehydrated, cleared in xylene,
then embedded in parafﬁn. Osteoblastswere counted on sections stained
using Van Gieson's, and osteoclasts counted on sections stained for
tartrate-resistant acid phosphatase (TRAP) activity. Standardized periph-
eral locations from the metaphysis were measured in a ﬁxed region of
interest. Mineralizing surfaces were measured from calcein-labeled,
undecalciﬁed bone sections. Tibias ﬁxed in 70% ethanol were dehydrated
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(transverse) plane. Sectionswere viewedusing a Zeiss Axioplan2ﬂuores-
cent microscope and captured using a SPOT® digital camera to image
labeled bone surfaces. Forming surface was calculated as the percentage
of non-eroded, single-labeled surface/total surface × 100 (MS/BS).
2.5. Biomechanical testing and micro-computed tomography (uCT)
Left tibias were stored damp at −20 °C before being allowed to
thaw at room temperature in PBS for 1 h. Specimens were tested in
three-point bending using a Vitrodyne V1000Material Testing system
as described previously (Hamrick et al., 2006b, 2008). Tibias were
mounted antero-posteriorly on stainless steel ﬁxtures 5 mm apart, ap-
proximately 2.5 mm either side of center. Testing was linear displace-
ment control with a displacement speed of 10 μm/s using a Transducer
Techniques 5 kg load cell. Structural, or extrinsic, properties including
ultimate force (Fu; height of curve) and stiffness (S; slope of curve)
were calculated from load–displacement curves. MicroCT images of the
right tibia were scanned using Bruker Skyscan1174 compact micro-CT
(Belgium), software version 1.5 (build 9) using NRecon version 1.6.4.8
for reconstructed images.
2.6. PCR and Western blotting
Total RNAwas extracted using Trizol and cDNAwas synthesized using
Quantitect reverse transcription kit (catalog no. 205310; Qiagen). Expres-
sion was analyzed quantitatively bymeans of the Quantitect SYBR Green
PCR kit (catalog no. 204143, Qiagen), and QuantiTect Primer Assays.
We used speciﬁc primers provided by QuantiTect Primer Assays for
Myostatin, Murf1, MaFbx, MHC, IGF-1, Runx2, Osx, BMP-2 and 18S,
GAPDH and β-actin (internal controls; Table 1). Half of each extensor
digitorum longus muscle was snap-frozen in liquid nitrogen for Western
blotting. Each muscle was placed in phosphate buffered saline (PBS) and
subjected to homogenization using Fisherbrand Tissuemiser® rotary ho-
mogenizer until large pieces of muscle were no longer visible. Samples
were subjected to two freeze–thaw cycles to disrupt the plasma mem-
brane then centrifuged brieﬂy. Protein concentrations were measured
using a commercial BCA reagent (Pierce, Rockford, IL) to ensure equal
loading. 30 μg of proteins from whole tissue lysates was mixed 1:1 withTable 1
Nucleotide sequences of mouse primers used for RT-PCR.
Gene Primer Reference/Accession number
GAPDH CAT GGC CTC CAA GGA GTA AGA
GAG GGA GAT GCT CAG TGT TGG
M32599
18S AGT GCG GGT CAT AAG CTT GC
GGG CCT CAC TAA AC CAT CCA
V00851
β-actin GTT TGA GAC CTT CAA CAC CCC
GTG GCC ATC TCC TGC TCG AAG TC
Meredith et al. (2011)a
Mstn ACT GGA CCT CTC GAT AGA ACA CTC
ACT TAG TGC TGT GTG TGT GGA GAT
NM_010834.2
IGF-1 CAG ACA GGA GCC CAG GAA AG
AAG TGC CGT ATC CCA GAG GA
NM_184052
MHC ACA GTC AGA GGT GTG ACTC AGC CG
CCG ACT TGC GGA GGA AAG GTG C
NM_001099635
Murf1 GGAGCAGCTGGAAAAGTCCACC
AGCTGCTTGGCACTTGAGAGGA
NM_001039048.2
Mafbx CAGCTTCGTGAGCGACCTC
GGCAGTCGAGAAGTCCAGTC
NM_026346
BMP-2 TGT TTG GCC TGA AGC AGA GA
TGA GTG CCT GCG GTA CAG AT
NM_007553.2
RUNX-2 GGA AAG GCA CTG ACT GAC CTA
ACA AAT TCT AAG CTT GGG AGG A
NM_009820
Osx ACT ACC CAC CCT TCC CTC AC
ACT AGG CAG GCA GTC AGA CG
AY803733
a Meredith ME, Harrison FE, May JM. Differential regulation of the ascorbic acid
transporter SVCT2 during development and in response to ascorbic acid depletion.
Biochem Biophys Res Commun. 2011 Nov 4;414(4):737–42.2× sample buffer and then applied to 4–20% polyacrylamide gels. Sam-
ples were electrophoretically separated and transferred to nitrocellulose
membrane (Invitrogen Corporation, Carlsbad, CA). The membranes
were incubated with speciﬁc primary antibodies MURF1 (Abcam cat.
77577) or MAFbx ( Santa Cruz Biotechnology, Inc. cat. 166806) and
then incubated with anti-mouse or anti-rabbit peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, Inc., CA). After the incu-
bation, the membranes were washed three times for 15 min each with
1× TTBS solution and then incubated with 1 ml of chemiluminescence
reagent (Invitrogen Corporation). The protein bands were visualized
using X-ray ﬁlms (Thermo Fisher Scientiﬁc, Rochester, NY).
2.7. Statistical analysis
Single-factor ANOVA with treatment group as the factor was used
to for pairwise comparisons of morphometric and histomorphometric
parameters. For analysis of gene expression data, the control genes of
18S and Actin were averaged to obtain an average control gene for
muscle tissue while GAPDH was used as the control gene for bone.
Difference in control gene Ct expression between GDF-8 and vehicle
was assessed using a two-sample t-test. Delta Ct values for each treat-
ment group were calculated as ΔCt = CtTarget gene − CtControl
gene. The difference in ΔCt expression between GDF-8 and vehicle
was assessed using a two-sample t-test. The magnitude of the differ-
ence between the groups was estimated using ΔΔCt values for each
target gene and these were calculated as ΔΔCt = ΔCtGDF-8 −
ΔCtvehicle and fold change was calculated as 2 to the power−ΔΔCt.
SAS® version 9.3 (SAS Institute, Inc., Cary, NC) was used for all analy-
ses and alpha = 0.05 was used to determine statistical signiﬁcance.
3. Results
3.1. Myostatin propeptide increases muscle mass and ﬁber size in aged
mice
Body weight of the vehicle- and propeptide-treated animals was
similar at the end of the study (Fig. 2A). Each treatment group did,
however, lose some weight over the treatment period but this was
less dramatic for the treated animals, such that their decrease in
body weight from day 0 to day 25 was signiﬁcantly less than that of
the vehicle-treated mice (Fig. 2B). Muscle mass of the tibialis anterior
was signiﬁcantly increased in the treated mice, both absolutely
(Fig. 3A) and relative to body weight (Fig. 3B). Fiber size of the pre-
dominantly fast-twitch extensor digitorum longus (EDL) muscle
was also signiﬁcantly increased by more than 15% in the treated mice
(Fig. 3C,D), whereas the increase in muscle ﬁber size in the predomi-
nantly slow-twitch soleus (SOL)muscle was also increased signiﬁcantly
(Fig. 3E) but by a lesser magnitude (~5%). Propeptide treatment
produced a slight but non-signiﬁcant increase in the expression of
myostatin itself, as well as expression of myosin heavy chain and
IGF-1 (Fig. 4A). Surprisingly, expression of the ubiquitin ligases Murf1
and Mafbx was signiﬁcantly increased with propeptide treatment
(Fig. 4A), and the PCR data were further validated by Western blot
(Fig. 4B).
3.2. Myostatin inhibitor does not alter bone formation or bone strength
in aged mice
MicroCT data from the tibia show that bone mineral density is
actually slightly higher (3%) in the tibias of vehicle-treated mice
(Table 2), but other parameters such as bone volume relative to
total volume, trabecular number, and trabecular thickness are similar
between the two groups (Table 2). Likewise, three-point bending
tests of tibias show that ultimate force, stiffness, and toughness (energy
to fracture) are also similar between the vehicle- and propeptide-
treated mice (Table 2). Bone histomorphometry data reveal that
Fig. 2. Body mass (A) and change in body weight (B) for animals treated with either
saline (VEH) or myostatin propeptide (PRO) weekly for over four weeks.
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mental groups (Table 3). Fluorochrome labeling showed double-labels
in only three mice from each group, and so single-labeled surfaces
were compared. Actively mineralizing surfaces were also similar be-
tween the two groups of mice (Table 3). Gene expression data showFig. 3.Muscle parameters for mice treated with saline (VEH) or myostatin propeptide (PRO
relative to body weight, (C) extensor digitorum longus ﬁber diameter (EDL), (D) alpha-lamno signiﬁcant differences in the expression of osteogenic genes Osx or
Runx2 with propeptide treatment, however the expression of BMP-2 is
increased in animals receiving the propeptide (Fig. 4C).
4. Discussion
Pharmacological inhibition of myostatin has, to date, been pursued
using a variety of in vivo approaches. These include utilization of
myostatin-speciﬁc antibodies (Bogdanovich et al., 2002; LeBrasseur
et al., 2009;Murphy et al., 2010;Wagner et al., 2008), a decoymyostatin
receptor (ActRIIB-Fc; Bialek et al., 2008; Borgstein et al., 2009; Chiu
et al., 2013; Lee et al., 2005), and myostatin propeptide (Bogdanovich
et al., 2005; Hamrick et al., 2010b). Published data now exist in which
each of these therapies has been evaluated in aged rodents, so that
some comparison of the different approaches can be undertaken. Our
data using amyostatin propeptide are consistentwith data from studies
using myostatin antibodies, where these myostatin inhibitors were
found to have signiﬁcant, positive effects on muscle mass, ﬁber size,
and muscle force production. Speciﬁcally, LeBrasseur et al. (2009)
used a slightly higher dose (25 mg/kg) than we used in our study
(20 mg/kg), but also used weekly injections of a myostatin inhibitor
(PF-354 antibody) over a period of 4 weeks in mice 24 months of age.
They too found a moderate (b10%) in muscle mass and a signiﬁcant in-
crease inmusclemass relative to bodyweight (+12–17%), aswe did for
the tibialis anterior muscle relative to body weight (+~15%). Murphy
et al. (2010), like LeBrasseur et al. (2009), used weekly doses of the
PF-354 antibody but used a lower dose (10 mg/kg) for a longer treat-
ment period— 14 weeks of treatment starting in mice aged 18 months.
These authors found increases in overall muscle mass (b10%) in the
gastrocnemius and quadriceps of the aged mice following 14 weeks
of treatment, and a signiﬁcant increase in (+12%) in muscle ﬁber
cross-sectional area of the tibialis anterior muscle, that were similar
in magnitude to the changes we observed with propeptide treatment.
Together, these studies using myostatin antibodies and our study
using the myostatin propeptide show similar increases in muscle ﬁber
size and muscle mass using either a low dose (10 mg/kg) over a longer
(14 week) treatment period, or a higher dose (20–25 mg/kg) over a
shorter treatment period (4 weeks).) weekly for a period of four weeks. (A) Tibialis anterior mass, (B) tibialis anterior mass
inin stained cryostat sections of the EDL, (E) soleus muscle ﬁber diameter.
Table 3
Bone histomorphometry data for the distal femur of mice treated with saline (VEH)
or myostatin propeptide (PRO; 20 mg/kg).N.Ob/BS = osteoblast number per bone sur-
face, MS/BS = mineralizing surface (single-label) relative to bone surface, N.Oc/BS =
osteoclast number per bone surface.
Parameter VEH (n = 15) PRO (n = 14) P value
N.Ob/BS (#/mm) 27.26 ± 17.49 25.09 ± 9.31 .14
MS/BS (%) 0.41 ± 0.17 0.43 ± 0.13 .34
N.Oc/BS (#/mm) 6.33 ± 2.61 6.18 ± 3.82 .38
Fig. 4. Real-time PCR data for mice treated with saline (VEH) or myostatin propeptide
(PRO) weekly for a period of four weeks showing increased expression of Murf1 and
Mafbx in PRO-treated mice (A), Western blot showing similar increases in Murf1 and
Mafbx with PRO-treatment (B), and increased expression of BMP-2 in mice treated
with propeptide (C). *P b .05.
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propeptide differ in two important ways from those utilizing the decoy
myostatin receptor (ActRIIB-Fc). First, a 10 mg/kg dose of ActRIIB-Fc ad-
ministered twice weekly for four weeks increased tibialis anterior mass
by 30% and quadriceps mass by 25% (Chiu et al., 2013). These increases
in muscle mass are much greater than those observed with either the
myostatin antibody or propeptide, which as noted above generated in-
creases in totalmusclemass of b10%. It is possible that these differences
could be due to the more frequent administration of the ActRIIB-Fc, but
the ActRIIB-Fc dose is much lower than that used in either our study or
the study by LeBrasseur et al. (2009), suggesting that the ActRIIB-Fc is aTable 2
microCT and biomechanical testing of the proximal tibia for mice treated with
saline (VEH) or myostatin propeptide (PRO; 20 mg/kg). BMD = bone mineral density,
BV/TV = bone volume relative to total volume, Tb.Th = trabecular thickness, Tb.N =
trabecular number, Fu = ultimate force, U = energy-to-fracture, S = stiffness.
Parameter VEH (n = 14) PRO (n = 15) P value
BMD (mg/cm3) 1.43 ± 0.06 1.38 ± 0.05 .01
BV/TV (%) 6.67 ± 2.37 6.14 ± 2.16 .24
Tb. Th (mm) 0.11 ± 0.02 0.11 ± 0.01 .47
Tb. N (mm) 0.59 ± 0.14 0.54 ± 0.16 .23
Fu (kg) 2.21 ± .40 2.18 ± .34 .39
U (kg/um2) 740.6 ± 417.5 670.3 ± 309 .31
S (g/um) 4.6 ± 2.0 4.7 ± 2.0 .44more potent molecule for increasing muscle mass in aged mice. The
reason for the greater potency of the ActRIIB-Fc for increasing muscle
mass is likely because this molecule can bind several ligands in addition
to myostatin, including activin, BMP-3, BMP-7, BMP-9, BMP-10, and
GDF-11 (Souza et al., 2008). Some of these molecules, such as activin,
are also likely to play a role in regulating muscle mass, which is further
indicated by the fact that ActRIIB-Fc treatment can increase muscle
mass in mice that lack myostatin altogether (Lee et al., 2005).
The second way in which our data differ from those using
ActRIIB-Fc is related to the effects on bone. ActRIIB-Fc treatment
was previously documented to increase bone formation and bone mass
in young, growing mice (Bialek et al., 2008), and the data from Chiu et
al. (2013) are consistent with this earlier report in showing that
ActRIIB-Fc increases bone density and serummarkers of bone formation
in agedmice after just 30 days of treatment. In contrast, our data revealed
no bone effectswithmyostatin propeptide treatment. These datamay in-
dicate that, as proposed by Chiu et al. (2013), the anabolic effects of
ActRIIB-Fc on bone are due to antagonizing effects on ligands other
than myostatin, such as various BMPs or activin. There are several addi-
tional points to consider though when comparing the effects of the two
inhibitors. If increases in muscle mass with inhibitor treatment might
prevent or delay, not necessarily reverse, bone loss then a myostatin
propeptide or antibody could be a safe and effective prophylactic ap-
proach for age-related bone loss. Also, if the primary mechanism by
which a myostatin inhibitor impacts bone is via its indirect effects on
bone, as opposed to direct effects on osteoblasts or osteoclasts, then a
four-week treatment period may not be sufﬁcient to induce a detectable
effect on bone. It has been observed, for example, that myostatin knock-
out mice do not show a decline in bone mass (BMC) with age whereas
they do show a moderate decline in bone density (BMD), similar to that
observed in normal mice (Morissette et al., 2009).
Previous work in our lab showed that myostatin can inhibit the pro-
liferation of aged bone marrow stromal cells (Bowser et al., 2013), that
bonemarrow stromal cells frommice lackingmyostatin show increased
proliferation (Elkasrawy et al., 2011), and that myostatin can inhibit
chondrogenesis in vivo and in vitro (Elkasrawy et al., 2012). These
data may at least in part explain the increased fracture callus size fol-
lowing osteotomy in mice lacking myostatin (Kellum et al., 2009), and
increased fracture callus bone volume in mice treated with myostatin
propeptide following osteotomy (Hamrick et al., 2010b). That is,
myostatin seems to play a key role in musculoskeletal injury repair,
one in which myostatin secretion from muscle is elevated following
muscle damage, and then mediates the repair response in adjacent
bone by modulating progenitor cell proliferation (Elkasrawy et al.,
2012). On the other hand, myostatin appears to have a more limited
role in mature, intact bone. This is indicated by the fact that myostatin
itself is not expressed at a signiﬁcant level by osteoblasts (Digirolamo
et al., 2011), and that myostatin inhibition via propeptide treatment
in adult mice does not signiﬁcantly alter osteoblast number, mineraliz-
ing surfaces, or bone strength (Tables 2 and 3). Thus, therapeutic
targeting ofmyostatin speciﬁcally via antibody or propeptide treatment
may have clinical application in the context of improving muscle mass
alone, or improving the healing of muscle and bone following injury,
but is not likely to have a signiﬁcant impact on bone formation in the in-
tact, aged animal. In contrast, the decoymyostatin receptor (ActRIIB-Fc)
appears capable of increasing muscle mass, bone formation, and bone
903P. Arounleut et al. / Experimental Gerontology 48 (2013) 898–904strength in aged rodents, suggesting that this molecule may have po-
tential clinical use for age-associated loss of both muscle and bone in
the form of sarcopenia and osteoporosis. A key step in developing the
decoy receptor as a targeted and safe therapeutic will be to identify
the speciﬁc ligands associated with the bone and muscle effects ob-
served in the soluble receptor-treated animals.
Muscle and bone are closely associated spatially and in terms of
structure and function during growth, development, and aging. Muscle
in particular has been considered a driving force for bone modeling
and remodeling, in that muscle is the primary source of mechanical
stimuli for bone and bone tissue is thought to adapt its gross structure
in response tomuscle-derived stimuli. Thus, targetingmuscle therapeu-
tically is thought to be one approach for improving bone health, simply
by enhancing themechanical relationship betweenmuscle and bone. On
the other hand, a large portion of osteoporotic fractures do not occur in
individuals with low bone density as measured by two-dimensional
densitometry, and so fall prevention alone may be another strategy for
reducing falls and fall-associated morbidity and mortality in the elderly
(Jarvinen et al., 2008). Behavioral interventions such as resistance exer-
cise or nutritional interventions such as vitamin D supplementation
(Girgis et al., 2013) may improve muscle strength and/or neuromuscu-
lar control and proprioception, perhaps reducing fall risk. The extent to
which myostatin inhibition may augment such strategies remains rela-
tively unexplored. Mice are relatively small in body weight and their
bones are capable of withstanding loads many times their own body
mass — for example it takes more than 2 kg of force to fracture the
tibia of a 32 g mouse (Table 2). Thus, increases in muscle mass in
these small mammals may not signiﬁcantly alter the mechanical envi-
ronment of their bones. Additional studies in patient populations are
needed to determine the extent to which therapeutic targeting of mus-
cle alone via amyostatin antibody or propeptide, perhaps in conjunction
with an exercise regimen, could reduce the incidence of bone fractures
versus a molecule such as ActRIIB-Fc, that may potentially increase the
mass and strength of both muscle and bone.
5. Conclusions
We tested the hypothesis that in vivo inhibition of myostatin using
an injectable myostatin propeptide (GDF8 propeptide-Fc) would in-
crease both muscle mass and bone density in aged (24 months) mice.
Our goal was to evaluate this potential therapeutic for its capacity to in-
crease both muscle and bone mass in the setting of age-associated
sarcopenia and osteoporosis. Mice were injected weekly (20 mg/kg
body weight) with recombinant myostatin propeptide-Fc (PRO) or vehi-
cle (VEH; saline) for four weeks. The data show that PRO treatment sig-
niﬁcantly increases muscle ﬁber size and muscle mass, both absolutely
and relative to body weight. In contrast bone volume, bone strength,
and histomorphometric parameters of bone formation and bone resorp-
tion were unchanged with PRO treatment. Our ﬁndings are consistent
with previous studies utilizing a myostatin antibody in aged mice show-
ing that targeting myostatin increases muscle ﬁber size and mass; how-
ever, our data differ from work utilizing a decoy myostatin receptor
(ActRIIB-Fc) to inhibit myostatin function in that ActRIIB-Fc appears par-
ticularly effective at increasing bone density and bone formationwhereas
the propeptide does not. The anabolic effects of ActRIIB-Fc on aged bone
are likely due to the ability of this molecule to antagonize other ligands
besides myostatin, such as activin or bone morphogenetic proteins.
Clinical trials evaluating the potential of these molecules to prevent falls
and fractures are needed to determine the optimal approaches for reduc-
ing musculoskeletal diseases and complications in the elderly.
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